CD274 and breast cancer: Compared to other subtypes of breast cancer, TNBC exhibits higher tumor mutational burden (TMB), increased tumor-infiltrating lymphocytes (TILs), and elevated programmed cell death 1 ligand 1 (PD-L1) expression, suggesting enhanced immunogenicity and potential responsiveness to immune checkpoint inhibitors (ICI).